Novel Therapies for Familial Hypercholesterolemia.
Both HeFH and HoFH require dietary and lifestyle modification. Pharmacotherapy of adult HeFH patients is largely driven by the American Heart Association (AHA) algorithm. A high-potency statin is started initially with a goal low-density lipoprotein cholesterol (LDL-C) reduction of >50 %. The LDL-C target is adjusted to <100 or <70 mg/dL in subjects with coronary artery disease (CAD) with ezetimibe being second line. If necessary, a third adjunctive therapy, such as a PSCK9 inhibitor (not yet approved in children) or bile acid-binding resin, can be added. Finally, LDL-C apheresis can be considered in patients with LDL-C >300 mg/dL (or >200 mg/dL with significant CAD, although now approved for LDL-C as low as 160 mg/dL with CAD). Due to the early, severe LDL-C elevation in HoFH patients, concerning natural history, rarity of the condition, and nuances of treatment, all HoFH patients should be treated at a pediatric or adult center with HoFH experience. LDL-C apheresis should be considered as early as 5 years of age. However, apheresis availability and tolerability is limited and pharmacotherapy is required. Generally, the AHA algorithm with reference to the European Atherosclerosis Society Consensus Panel recommendations is reasonable with all patients initiated on high-dose, high-potency statin, ezetimibe, and bile acid-binding resins. In most, additional LDL-C lowering is required with PCSK9 inhibitors and/or lomitapide or mipomersen. Liver transplantation can also be considered at experienced centers as a last resort.
Stanford University Medical Center, 300 Pasteur Ave, Stanford, CA, 94305, USA.
Justin
J
Parizo
Stanford University Medical Center, 300 Pasteur Ave, Stanford, CA, 94305, USA.
Ashish
A
Sarraju
Stanford University School of Medicine and Cardiovascular Institute, Falk CVRC, 300 Pasteur Drive, MC 5406, Stanford, CA, 94305, USA. knowlej@stanford.edu.
Joshua W
JW
Knowles
Familial hypercholesterolemia; LDL-C; Lomitapide; Mipomersen; PCSK9 inhibitor; Statin